ArticleAmerican journal of translational research2016
MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- YRDC is a Prognostic-Related Biomarker Correlated With Immune Infiltration and Drug Sensitivity in Pan-Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Nuclear Receptors in Bladder Cancer: Insights into miRNA-Mediated Regulation and Potential Therapeutic Implications.International journal of molecular sciences · 2025Review
- Epigenetic modifications in bladder cancer: crosstalk between DNA methylation and miRNAs.Frontiers in immunology · 2025Review
- Panel containing three serum microRNAs: a promising biomarker for early detection of bladder cancer.Frontiers in oncology · 2024Article
- The action and resistance mechanisms of Lenvatinib in liver cancer.Molecular carcinogenesis · 2023Review
- Article
- c-Met: A Promising Therapeutic Target in Bladder Cancer.Cancer management and research · 2022Review
- Long Non-coding RNA RMRP in the Pathogenesis of Human Disorders.Frontiers in cell and developmental biology · 2021Review
- MicroRNAs and target molecules in bladder cancer.Medical oncology (Northwood, London, England) · 2020Review
- YRDC is upregulated in non-small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis.Oncology letters · 2020Article
- MicroRNAs: Key Players in Bladder Cancer.Molecular diagnosis & therapy · 2019Review
- Increased miR-323a induces bladder cancer cell apoptosis by suppressing c-Met.The Kaohsiung journal of medical sciences · 2019Article
- Matching tRNA modifications in humans to their known and predicted enzymes.Nucleic acids research · 2019Article
- MiR-206 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting theOncoTargets and therapy · 2019Article
- Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma.Clinical epigenetics · 2018Article
- miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9.Cancer medicine · 2017Article
- Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.International journal of molecular sciences · 2017Review
- MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer.Cancer cell international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence suggested that microRNA (miRNA) plays important regulatory roles in the initiation and development of various cancers. Previous study showed that microRNA-206 (miR-206) is dysregulated in human bladder cancer tissues, however, the biological function and underlying mechanisms of miR-206 in human bladder cancer remain unknown. In the present study, we aimed to investigate the clinical significance of miR-206 and its target gene YRDC in human bladder cancer, and to determine its effects on oncogenic phenotypes of this disease. Our results showed that miR-206 expression was downregulated significantly in bladder cancer tissues and cell lines compared with adjacent normal bladder tissues and human bladder epithelial immortalized SV-HUC-1 cell line, respectively. Overexpression of miR-206 reduced the expression of YRDC and inhibited bladder cancer cell proliferation, colony formation, migration, invasion and induced cell cycle arrest at G0/G1 phase. In addition, knockdown of YRDC exhibited similar effects with miR-206 overexpression in bladder cancer cells and restoration of YRDC partially reversed the effects of miR-206 in bladder cancer cells. These findings indicated that mir-206 might be a novel target for bladder cancer therapy by targeting YRDC.
Indexed as
Identifiers
27904673PMC5126315W2560667767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.